Illumina, Inc.
905 articles with Illumina, Inc.
-
Illumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressing Need for Global Access to Genomics
8/8/2022
Illumina, Inc. (NASDAQ: ILMN), today announced that on September 30, its Illumina Genomics Forum (IGF) will feature Bill Gates, co-chair of the Bill & Melinda Gates Foundation, who will deliver a keynote address on the remarkable potential of genomics to change the trajectory of global health.
-
Illumina Unveils its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities
7/27/2022
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the release of Illumina DRAGEN™ v4.0, its most accurate and comprehensive secondary analysis platform.
-
Illumina to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
7/14/2022
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2022 following the close of market on Thursday, August 11, 2022.
-
Illumina Among First in the World to Receive Approval of Science-Based Net-Zero Target
7/14/2022
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced it is among the first group of companies worldwide to receive approval of its net-zero targets by the Science Based Targets initiative.
-
Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health
6/28/2022
Illumina, Inc. announced its participation in Time Boost Capital I LP, a £30 million genomics venture fund dedicated to providing match funding to startups graduating from Illumina Accelerator Cambridge with the aim to advance breakthroughs in human health.
-
Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome
6/22/2022
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced the launch of a research test, codeveloped with Merck.
-
Joydeep Goswami Appointed Interim CFO; Sam Samad to Depart Illumina
6/9/2022
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced Joydeep Goswami, Chief Strategy and Corporate Development Officer, will also serve as interim Chief Financial Officer while the company conducts a search for a permanent CFO.
-
Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions
6/7/2022
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, shared key customer-focused announcements and presentations it will make at the Advances in Genome Biology and Technology General Meeting, taking place June 6–9 in Orlando, Fla.
-
Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO
6/2/2022
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the acceptance of seven key oncology research abstracts authored in collaboration with Illumina at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 3 – June 7 in Chicago.
-
Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy
5/24/2022
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced the addition of a companion diagnostic indication to its CE-marked in vitro diagnostic TruSight™ Oncology Comprehensive test.
-
Illumina and Deerfield Management have entered into a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies.
-
Illumina and Deerfield Management partner to accelerate drug development
5/5/2022
Illumina, Inc. announced a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies for diseases with unmet medical needs.
-
Illumina Reports Financial Results for First Quarter of Fiscal Year 2022
5/5/2022
Illumina, Inc. announced its financial results for the first quarter of fiscal year 2022, which include consolidated financial results for GRAIL.
-
Illumina To Webcast Upcoming Investor Conference - Apr 28, 2022
4/28/2022
Illumina, Inc. announced that its executives will be speaking at the following investor conference:.
-
Illumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children
4/25/2022
Illumina, Inc. announced an agreement with Germany's Hannover Medical School to implement the use of whole-genome sequencing in critically ill children suspected of having a genetic or rare disease.
-
Illumina to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
4/14/2022
Illumina, Inc. (NASDAQ: ILMN) today announced that it will issue results for the first quarter 2022 following the close of market on Thursday, May 5, 2022.
-
BMS filed a patent infringement lawsuit against AstraZeneca over Imfinzi, while Guardant Health issued a statement in response to Illumina's intellectual property lawsuit.
-
Guardant Health Response to Frivolous and Retaliatory Lawsuit Filed by Illumina
3/17/2022
Guardant Health, Inc. today provided the following statement regarding a lawsuit filed by Illumina that seeks to challenge Guardant Health’s ownership and authorship of a portion of its intellectual property and to suppress competition in the market.
-
Illumina Accelerator Invests in Seven Omics Startups Advancing Breakthrough Therapeutics, Diagnostics, DNA Storage, Mental Wellness, and Sustainable Foods Applications
3/16/2022
Illumina, Inc. (NASDAQ: ILMN) has invested in seven new genomics companies to join the fourth global funding cycle of Illumina Accelerator San Francisco Bay Area and Cambridge, UK.
-
Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe
3/15/2022
Illumina, Inc. announced the launch of TruSight™ Oncology Comprehensive, a single test that assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer.